Drugs / TQ-F3083
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03986073 | Jan → Jun 2020 | type 2 diabetes mellitus | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQ-F3083 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03986073 ↗ |
| Action | Inhibit | “TQ-F3083 capsule is a new type inhibitor of DPP-IV” NCT03986073 ↗ |